Direct Biologics to Support ARDS Alliance as Educational Sponsor

AUSTIN, Texas - EntSun -- Direct Biologics, LLC will serve as an Educational Sponsor of an upcoming educational webinar produced by ARDS Alliance, Inc. focused on Acute Respiratory Distress Syndrome, Extracellular Vesicle science, secretome research and investigational biologic approaches.

Supported through an educational grant from Direct Biologics, the webinar is being independently developed and produced by ARDS Alliance. The program is intended to provide patients, caregivers and other members of the ARDS community with accurate, science-based educational information and to help address common misconceptions surrounding investigational approaches, including their regulatory status.

The educational program will feature an independent physician or researcher as well as a patient perspective highlighting the experience and impact of ARDS. ARDS Alliance will independently select the speakers and maintain sole editorial control over the webinar and its educational content.

More on EntSun News

• Lovecraft In Florida Blu-Ray Release
• Retell AI White Label Platform for Agencies Launched by VoiceAIWrapper, With Branded Client Portals and No Per-Minute Markup
• Events by Dubsdread Celebrates Cultural Traditions with New Guide on Faith-Based Wedding Traditions Across Cultures
• FOCUS Names Mark Phillips Senior Vice President of Business Development
• Get The Led Out Bring an Outstanding Tribute to Led Zeppelin to the Weinberg Center

"The importance of independent, science-based education for patients and families, and our appreciation for the educational support that makes these programs possible, cannot be overstated," said Paula Blonski, President of ARDS Alliance.

"ARDS is a complex and serious condition, and access to credible, understandable scientific information is important for patients and families navigating it," said Tim Moseley PhD, CSO of Direct Biologics. "We are pleased to support ARDS Alliance in its efforts to provide independent education to the ARDS community."

Direct Biologics' sponsorship is limited to financial support of the educational program and does not provide the company with editorial control over the webinar. Sponsorship does not constitute an endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy.

The webinar is expected to take place later this year with the recording available through ARDS Alliance and Direct Biologics.

The ARDS Alliance is dedicated to improving ARDS outcomes. By collaborating with patient advocates, healthcare experts, and scientific researchers, the ARDS Alliance works to accelerate research, improve clinical recognition, and advance the global standard of care for respiratory failure.

More on EntSun News

• Cemetery Cinema is now available for Syndication!!!!
• Notaron Expands Online Notarization Access Following Wisconsin Approval
• Michelle Carey Releases Maryland Political Thriller, The Crofton Triangle
• Before Drake Was Drake, Detroit-Raised KayeDinero Was Already Watching Aubrey Graham
• Mountaineers Roll Out All-In-One Social Hub and Exclusive Content Vault on Brian Walton's Site

Direct Biologics (https://www.directbiologics.com/) develops investigational secretome-based products under cGMP standards, guided by scientific rigor. All candidate therapies are investigational and have not been approved by the U.S. Food and Drug Administration.

Important Notice
The ARDS Alliance webinar is an independent educational program produced and controlled solely by ARDS Alliance. Direct Biologics' sponsorship does not constitute endorsement by ARDS Alliance of Direct Biologics, its products or any specific therapy. Any investigational therapies discussed during the educational program are under investigation and have not been approved by the U.S. Food and Drug Administration for the indications discussed, unless expressly identified otherwise. The webinar is intended solely for educational purposes and is not intended to provide medical advice, establish a standard of care or recommend the use of any investigational or approved product.